ARO-ENaC

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameARO-ENaC

Drug Alias NameARO-Lung1

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionEpithelial sodium channel modulators

TargetsEpithelial sodium channel

Therapy Area/IndicationsPulmonary FibrosisCystic Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New ZealandNew ZealandAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsCystic Fibrosis

Inactive IndicationsPulmonary Fibrosis

ATC CodeN/A